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Abstract Streptozotocin (STZ)-induced diabetic animals are
vulnerable to cold stress. Uncoupling proteins (UCPs) play an
important role in regulating thermogenesis. We investigated the
gene expressions of UCPs in brown adipose tissue (BAT), white
adipose tissue (WAT), liver and gastrocnemius muscle of STZ-
diabetic rats using Northern blot. UCP-1, -2 and -3 mRNA
expressions in BAT were all remarkably lower in STZ-diabetic
rats than those in control rats. Both UCP-2 and -3 gene
expressions in gastrocnemius muscle were substantially elevated
in STZ-diabetic rats and insulin treatment restored UCP gene
expressions to normal levels. These results suggest that in STZ-
diabetic rats, the overexpression of UCP-2 and UCP-3 in
skeletal muscle provides a defense against hypothermogenesis
caused by decreased UCPs in BAT.
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1. Introduction
Brown adipose tissue (BAT) through the action of uncou-
pling protein (UCP)-1 plays an important role in regulating
thermogenesis in rodents [1]. UCP-1 is located at the inner
membrane of mitochondria, and translocates protons into the
matrix of mitochondria, resulting in heat production without
coupling to any other energy-consuming process [2,3].
Diabetes mellitus is known to have reduced cold tolerance
in human [4,5]. Alloxan or streptozotocin (STZ)-induced dia-
betic animals are also vulnerable to cold stress [6,7] because
thermogenesis is impaired in these animals. In fact, the weight
of BAT was found to be reduced in STZ-diabetic rats [8], and
the total amount of uncoupling protein content in BAT mi-
tochondria, the ability for L-oxidation, and mitochondria
GDP-binding were also decreased in these animals [9,10]. In-
sulin treatment reverses the uncoupling protein content and
the BAT thermogenesis in STZ-diabetic rats [8].
Recently, two cDNAs encoding the UCP homologs were
identi¢ed and called UCP-2 [11,12] and UCP-3 [13^16]. Tissue
distributions and expression pattern of these two genes were
di¡erent from UCP-1; e.g. UCP-1 mRNA is expressed specif-
ically in BAT [17,18], while UCP-2 mRNA is expressed in
numerous tissues such as white adipose tissue (WAT), BAT,
skeletal muscle and liver [11,12]. UCP-3 gene expression ap-
peared to be restricted in human and rodent muscle, and in
rodent BAT [13^16]. UCP-3 may act as a mediator of thermo-
genesis in human, because it is expressed at a high level solely
in human skeletal muscle, a major site of thermogenesis.
However, neither UCP-2 nor UCP-3 gene expression has
been reported in STZ-induced diabetic animals.
To investigate whether UCP gene expressions are altered in
STZ-diabetic rats, we determined the mRNA levels of UCP-1,
UCP-2 and UCP-3 in BAT, WAT, liver and gastrocnemius
muscle in these rats. The e¡ect of insulin treatment on UCP
gene expressions was also examined.
2. Materials and methods
2.1. Animals and procedures
Male Sprague-Dawley rats weighing 220^230 g (Japan SCL, Hama-
matsu, Japan) were used in all experiments. They were maintained in
individual cages on a rotating 12/12 h light/dark cycle with an ambient
temperature of 24 þ 1‡C, and were provided with free access to both
standard rat chow (Oriental Food, Tokyo, Japan) and water.
Animals were divided into three groups: (1) vehicle-treated control,
(2) STZ-induced diabetic, and (3) STZ-induced diabetic with insulin
treatment. After 5 h fast, each animal received an injection of STZ
(Sigma, St. Louis, MO, USA) at 75 mg/kg body weight in sodium
citrate bu¡er (pH 4.0) or sodium citrate bu¡er (pH 4.0) (vehicle)
through the tail vein (day 0 at 2:00 p.m.). Diabetes was diagnosed
24 h later (day 1 at 2:00 p.m.), and de¢ned as a blood glucose level
greater than 13.8 mmol/l (250 mg/dl) measured using a drop of
blood obtained by tail vein puncture. Insulin-treated STZ-diabetic
rats were subcutaneously injected with 4 U and 2 U human insulin
(NPH; Novo Nordisk, Copenhagen, Denmark) 29 h (day 1 at 7:00
p.m.) and 42 h (day 2 at 8:00 a.m.) after the STZ injection, respec-
tively.
On the day of experiments (day 2, 48 h later), food was withdrawn
at 8:00 a.m. and experiments were carried out after a 6-h fast. All
animals were killed by decapitation. Tissues (interscapular BAT, epi-
didymal WAT, liver and gastrocnemius muscle) were dissected and
blood was taken. Tissues were immediately frozen in liquid nitrogen
and stored at 380‡C until use. The blood was centrifuged at 4‡C, and
plasma was stored at 380‡C until assayed.
2.2. Measurements
Plasma glucose levels were determined by glucose oxidase method
(Glucose B-test, Wako Pure Pharmaceutical, Osaka, Japan). Immu-
noreactive insulin (IRI) concentrations were determined by a radio-
immunoassay kit (Cat#RI-13K, Linco Research, St. Charles, MO,
USA) standardized against rat insulin. Ketone bodies (acetoacetate
and L-hydroxybutyrate) were determined by the enzyme method using
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a commercially available kit (Ketone Teat Sanwa, Sanwa Kagaku
Laboratory, Nagoya, Japan). Plasma non-esteri¢ed fatty acid
(NEFA) concentration, plasma triglyceride concentration and plasma
total cholesterol concentration were determined by the enzyme meth-
od using a kit (NEFA-C test, triglyceride-G test and total cholesterol-
C test, respectively, all from Wako Pure Pharmaceutical).
2.3. RNA analysis
Total RNA was prepared from the tissue of each rat using TRIzol
reagent (Gibco-BRL, Frederick, MD, USA). The concentration of
RNA was determined spectrophotometrically. Total RNA was loaded
at 15 Wg per lane on a 1% agarose/formaldehyde gel and transferred
onto a nylon membrane (Hybond N, Amersham, Arlington Heights,
IL, USA). Membranes were hybridized with [K-32P]dCTP-labeled
cDNA probe for rat UCP-1, mouse UCP-2 and rat UCP-3. The
blot was exposed to X-ray ¢lm (Fuji Photo Film, Tokyo, Japan) at
380‡C using an intensifying screen. Signals were quanti¢ed with FU-
JIX Bio-Imaging Analyzer BAS2000 (Fuji Photo Film). Equivalent
loading was veri¢ed by the density of the methylene blue-stained
rRNAs bands after transfer.
2.4. Statistical analysis
Data are expressed as means þ standard error (SEM). Statistical
signi¢cance was assessed by one-way ANOVA.
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Table 1
Characteristic features of control (vehicle), STZ diabetic (STZ) and STZ diabetic rats with insulin treatment (STZ+insulin)
Vehicle (n = 5) STZ (n = 5) STZ+insulin (n = 5)
Initial BW (g) (0 h) 225 þ 3 222 þ 3 221 þ 2
% BW change (24 h) 1.96 þ 0.66 39.2 þ 0.50a 37.42 þ 0.45a
% BW change (48 h) 5.05 þ 0.90 319.0 þ 2.07a 32.34 þ 0.91a;b
Final BW (g) (48 h) 236 þ 3 180 þ 4a 216 þ 4a;b
Epididymal fat pads (g) 1.6 þ 0.1 1.2 þ 0.1a 1.4 þ 0.1
Food intake (0^24 h) (g) 20.0 þ 1.2 11.4 þ 0.4a 11.9 þ 1.3a
Food intake (24^48 h) (g) 18.5 þ 0.9 5.0 þ 2.5a 23.5 þ 1.6b
Plasma glucose (mmol/l) 4.27 þ 0.64 35.04 þ 6.78a 4.14 þ 1.59b
Total cholesterol (mmol/l) 0.86 þ 0.02 1.15 þ 0.22 0.80 þ 0.10
Triglyceride (mmol/l) 0.92 þ 0.08 4.32 þ 1.90 1.66 þ 0.23
NEFA (Wmol/l) 1139 þ 67 1900 þ 340a 1489 þ 101
Total ketone bodies (Wmol/l) 91.7 þ 7.1 5295.8 þ 148.7a 145.6 þ 12.3b
Plasma insulin (ng/ml) 2.90 þ 0.43 0.06 þ 0.03a 3.86 þ 0.73b
Data represent the means þ standard error (S.E.M.). Superscripts indicate statistical signi¢cance by one-way ANOVA at P6 0.05: a vs. vehicle-
control, b vs. STZ-diabetes. NEFA, non-esteri¢ed fatty acid.
Fig. 1. Northern blot analysis and quanti¢cation of the relative lev-
els of UCP mRNA in BAT. A: Autoradiograph of Northern blot
analysis. Vehicle: vehicle-treated control; STZ: STZ-induced dia-
betic rats; STZ+Ins: STZ-induced diabetic rats with insulin treat-
ment. B: UCP mRNA level. UCP mRNA levels normalized to total
RNA loaded. The y-axis indicates the relative level of UCP mRNA
(level of UCP mRNA of vehicle-treated control was designated as
1.0). V: vehicle-treated control rats; S: STZ-induced diabetic rats;
I: STZ-induced diabetic rats. Data are mean þ S.E. Di¡erent super-
scripts show that the means are signi¢cantly di¡erent from each
other: abP6 0.005; bcP6 0.0001; acP6 0.0001. Columns not sharing
the same superscript are signi¢cantly di¡erent.
Fig. 2. Northern blot analysis and quanti¢cation of the relative lev-
els of UCP-2 mRNA in WAT and liver. A: Autoradiograph of
Northern blot analysis. Upper panel shows UCP-2 gene expression
in WAT. Lower panel shows UCP-2 gene expression in liver. Ve-
hicle: vehicle-treated control; STZ: STZ-induced diabetic rats;
STZ+Ins: STZ-induced diabetic rats with insulin treatment. B:
UCP mRNA level. UCP-2 mRNA level normalized to total RNA
loaded. The y-axis indicates the relative level of UCP-2 mRNA (lev-
el of UCP mRNA of vehicle-treated control was designated as 1.0).
V: vehicle-treated control rats; S: STZ-induced diabetic rats; I:
STZ-induced diabetic rats. Data are mean þ S.E.
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3. Results
3.1. Group characteristics
Table 1 shows characteristic features in three groups of rats.
Body weight decreased about 45 g in STZ-induced diabetic
rats, while plasma concentrations of glucose, NEFA and ke-
tone bodies signi¢cantly increased (P6 0.05). Plasma insulin
levels in STZ-induced diabetic rats were signi¢cantly lower
than in control rats (P6 0.05). Body weight and plasma glu-
cose, NEFA and ketone body levels were restored to normal
by insulin treatment.
3.2. Gene expression levels of UCP-1, UCP-2 and UCP-3
In STZ-induced diabetic rats, UCP-1, UCP-2 and UCP-3
mRNA signi¢cantly decreased in BAT (Fig. 1), while expres-
sion of UCP-2 mRNA did not change in WAT or liver (Fig.
2). Levels of UCP-2 and UCP-3 mRNA in gastrocnemius
muscle were 4.4 and 2.0 times higher in STZ-diabetic rats
than in control rats, respectively (Fig. 3). The alteration of
UCP mRNA expressions in BAT and gastrocnemius muscle
in STZ diabetic rats were almost restored to normal by insulin
treatment (Figs. 1 and 3).
4. Discussion
Two new members of the UCP gene family have recently
been cloned, UCP-2 and UCP-3. Both diminish mitochondrial
membrane potential when they are transfected into yeast
[11,12,14], suggesting that, similar to UCP-1, these proteins
also contribute to both uncoupled-oxidative phosphorylation
and thermogenesis.
GeŁloeºn et al. [8] reported that total UCP content in BAT
was decreased in STZ-diabetic rats, and suggested that this
contributes to their vulnerablility to cold stress. In this study,
we found that UCP-1, UCP-2 and UCP-3 gene expressions
in BAT were all remarkably diminished in STZ-diabetic
rats, which may explain hypothermogenesis in these animals
[6,7].
Since there is little BAT in adult human [19], UCP-1 is not
likely to play a major role in thermogenesis in adult human.
UCP-3 may be involved in thermogenesis in human as well as
in rodent, because UCP-3 mRNA is expressed at a high level
in skeletal muscle [13,16]. Our novel ¢ndings in the present
study are that UCP-3 mRNA in gastrocnemius muscle was
signi¢cantly elevated in STZ-diabetic rats, and that insulin
treatment normalized this overexpression. Tsuboyama-Kasao-
ka et al. [20] reported that UCP-3 gene expression is positively
associated with glucose transporter-4 (GLUT4) gene expres-
sion in gastrocnemius muscle. According to their observation,
UCP-3 gene expression must be decreased because it is well
known that GLUT4 mRNA is reduced in STZ-diabetic ani-
mals [21]. We found, however, that UCP-3 gene expression
was markedly increased in these animals. Therefore, it is likely
that hyperglycemia itself does not increase UCP-3 gene ex-
pression. An increase in plasma NEFA level by high-fat diet
feeding [15] or intralipid infusion [22] leads to overexpression
of UCP-3 mRNA in gastrocnemius muscle of rodents. There-
fore, it is possible that an increase in NEFA enhances the
expression of UCP-3 mRNA, because STZ-diabetic rats had
substantially elevated NEFA levels. Ketone bodies are anoth-
er candidate for UCP-3 mRNA overexpression in these insu-
lin-de¢cient diabetic animals. Indeed, Guerin et al. [23] re-
ported that diabetic ketoacidosis is associated with
hypothermia. The issue of expression of UCP-3 mRNA by
ketone bodies needs further investigation.
Very recently Krook et al. [24] reported that UCP-3 mRNA
in femoral muscle was decreased in type 2 diabetic patients.
Their results do not contradict with our results: reduction of
UCP-3 with hyperinsulinemia in their patients vs. elevation of
UCP-3 with hypoinsulinemia in our diabetic rats.
Enerbaºck et al. [25] reported that UCP-2 mRNA was over-
expressed in BAT in UCP-1 null mice. Thus, compensatory
increase in UCP-2 may also contribute to prevention of hypo-
thermogenesis in these mice. In fact, UCP-2 gene expression
in the gastrocnemius muscle of STZ-diabetic rats signi¢cantly
increased, although the mechanism of overexpression of UCP-
2 mRNA is unknown.
In summary, we demonstrated for the ¢rst time that UCP-2
and UCP-3 gene expressions were increased in skeletal muscle
of STZ-induced diabetic rats, while UCP-1, UCP-2 and UCP-
3 gene expression were reduced in BAT of these rats, and
insulin treatment reversed all these abnormalities. We hy-
pothesize that overexpression of UCP-2 and UCP-3 gene
may change reciprocally between gastrocnemius muscle and
BAT to maintain thermogenesis.
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Fig. 3. Northern blot analysis and quanti¢cation of the relative lev-
els of UCP mRNA in gastrocnemius muscle. A: Autoradiograph of
Northern blot analysis. Vehicle: vehicle-treated control; STZ: STZ-
induced diabetic rats; STZ+Ins: STZ-induced diabetic rats with in-
sulin treatment. B: UCP mRNA level. UCP mRNA levels normal-
ized to total RNA loaded. The y-axis indicates the relative level of
UCP mRNA (level of UCP mRNA of vehicle-treated control was
designated as 1.0). V: vehicle-treated control rats; S: STZ-induced
diabetic rats; I: STZ-induced diabetic rats. Data are mean þ
S.E. Di¡erent superscripts show that the means are signi¢cantly
di¡erent from each other: abP6 0.001; cdP6 0.001; bcP6 0.0001;
acP6 0.0001.
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